杜皮鲁玛
医学
肉芽肿伴多发性血管炎
美波利祖马布
嗜酸性
嗜酸性粒细胞增多症
哮喘
免疫学
奥马佐单抗
嗜酸性粒细胞
过敏性支气管肺曲菌病
鼻息肉
肺嗜酸性粒细胞增多
白细胞介素5
苯拉唑马布
皮肤病科
坏死性血管炎
鼻窦炎
单克隆
血管炎
嗜酸性粒细胞增多
过敏性
作者
Albatol Rashed,Riyad Omar Al-Lehebi
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2025-09-27
卷期号:: PA5668-PA5668
标识
DOI:10.1183/13993003.congress-2025.pa5668
摘要
Unmasking of Eosinophilic Granulomatosis With Polyangiitis by the initiation of Dupilumab in severe asthma : A Case Series. Dupilumab, an anti-IL-4Rα monoclonal antibody, is effective in managing severe asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). However, its use has been associated with transient eosinophilia and, rarely, the unmasking of eosinophilic granulomatosis with polyangiitis (EGPA). We present two cases of severe asthma patients who developed EGPA following dupilumab initiation Case 1: A 52-year-old female with refractory eosinophilic asthma and CRSwNP, previously treated with omalizumab and mepolizumab, was started on dupilumab. While asthma control improved, she developed arthralgia, neuropathy, and pulmonary nodules. Elevated eosinophils and imaging findings led to an EGPA diagnosis. Dupilumab was discontinued, and mepolizumab 300 mg with corticosteroids induced remission. Case 2: A 43-year-old female with severe eosinophilic asthma and CRSwNP, unresponsive to mepolizumab, was initiated on dupilumab. Despite initial improvement, she developed arthritis, elevated eosinophils, and ground-glass opacities on imaging. EGPA was confirmed, and dupilumab was replaced with mepolizumab 300 mg, resulting in symptom resolution Both cases highlight the potential for dupilumab to unmask EGPA, likely due to its modulation of type 2 inflammation and eosinophil trafficking. Transient eosinophilia and most likely steroid tapering may exacerbate underlying vasculitic processes. Close monitoring of eosinophil levels and clinical symptoms is essential when initiating dupilumab, particularly in patients with severe asthma and elevated eosinophils
科研通智能强力驱动
Strongly Powered by AbleSci AI